Insider buying · SEC Form 4

Insider Buying — Aug 4, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

2insider buys
$11.0Mbought in total
2companies
1by CEOs, CFOs and other chiefs
LBRXlargest: $10.0M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
LBRXLB Pharmaceuticals Inc.David Kroin / Deep Track Capital, LP10% Owner$10.0M286,205$34.94AddedAug 3, 2026
Form 4 ↗
Purchased 286,205 pre-funded warrants at $34.94 avg (PIPE/negotiated private placement). LBRX now at $42.84 (+22.6% from buy price). Deep Track Capital is a specialist biotech long-only fund; 9.99% ownership cap. Extremely illiquid — wide $31/$50 bid/ask spread, 33 shares daily volume; price not fully reliable. Transaction code P per Form 4.
HUNHuntsman CorporationPeter R. HuntsmanChairman, President & CEO$981K100,000$9.81AddedAug 3, 2026
Form 4 ↗
Open-market purchase on Aug 3 at $9.81 weighted avg (range $9.76–$9.89). HUN now at $10.02 (+2.1% since buy). CEO adds to 7.26M direct shares (+1.4% to direct stake). Specialty chemicals company under pressure from soft demand; Huntsman buying near apparent cycle lows.

AIThe day in insider buying

SEC Form 4 Insider Scan — August 4, 2026

Scanned the last 24 hours of EDGAR Form 4 filings (filed August 3–4, 2026; 246+ total Form 4s in window). 2 qualifying buys (≥ $250K, transaction type P) totalling ~$10.98M.

Headline Filings

  • LBRX — Deep Track Capital / David Kroin (10%+ Owner) purchased 286,205 pre-funded warrants ≈ $10.0M at $34.94 avg; now $42.84 (+22.6% since buy). (filing)
  • HUN — Peter R. Huntsman (Chairman, President & CEO) bought 100,000 shares ≈ $981K at $9.81 avg; now $10.02 (+2.1% since buy). (filing)

Notes

Biotech — LBRX: Deep Track Capital committed $10M to LB Pharmaceuticals via pre-funded warrants (likely a PIPE / negotiated private placement). Deep Track is a specialist biotech long-only fund known for concentrated, conviction-driven positions. The structure includes a 9.99% beneficial ownership cap — standard for institutional PIPE investors. LBRX is extremely illiquid (33 shares of reported daily volume); the price quote ($42.84 last, $31/$50 bid/ask spread) may not reflect reliable fair value. Still, the $10M commitment represents a meaningful vote of confidence.

Specialty Chemicals — HUN: CEO Peter Huntsman made an open-market purchase of 100,000 shares at $9.81 weighted average on August 3 — the same day the filing was submitted. HUN now trades at $10.02, up 2.1% since the buy. Huntsman already owned 7.26M direct shares and 933K indirect; this adds ~1.4% to his direct stake. The purchase at sub-$10 levels suggests the CEO views current prices as a cyclical low — HUN has been under pressure from soft chemical demand and raw material cost headwinds.

Overall: Light day for qualifying insider purchases. The vast majority of the 246+ Form 4s filed were routine 10b5-1 plan sales, RSU vestings, tax withholdings, and equity award grants. The two qualifying buys represent non-routine capital commitment by insiders with inside knowledge of their companies.

Most-bought stocks, last 30 days

  • AVO $60.1M · 8 buysMission Produce, Inc.
  • SCTX $56.3M · 3 buys, 3 insidersScribe Therapeutics Inc.
  • COE $26.7M · 3 buys, 2 insiders51Talk Online Education Group
  • MPLT $15.3M · 1 buyMapLight Therapeutics, Inc.
  • FLUT $11.8M · 1 buyFlutter Entertainment plc
  • LBRX $10.0M · 1 buyLB Pharmaceuticals Inc.
  • NTSK $7.53M · 2 buys, 2 insidersNetskope Inc.
  • PBLS $6.92M · 1 buyParabilis Medicines, Inc.
  • HDSN $6.49M · 3 buys, 2 insidersHudson Technologies, Inc.
  • GLOO $3.50M · 1 buyGloo Holdings, Inc.
  • ARTV $2.58M · 1 buyArtiva Biotherapeutics, Inc.
  • ACI $2.41M · 2 buys, 2 insidersAlbertsons Companies, Inc.
  • NVCT $2.33M · 4 buys, 2 insidersNuvectis Pharma, Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • CLBK $2.13M · 5 buys, 5 insidersColumbia Financial, Inc.
  • GGAL $2.09M · 1 buyGrupo Financiero Galicia S.A.
  • ENR $2.02M · 1 buyEnergizer Holdings, Inc.
  • RH $1.83M · 1 buyRH
  • FULC $1.48M · 2 buys, 2 insidersFulcrum Therapeutics, Inc.
  • BOLD $1.25M · 3 buys, 2 insidersBoundless Bio, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.